Fertilitätsprotektion bei onkologischen und nichtonkologischen Erkrankungen

von Wolff M, Yding Andersen C, Woodruff T et al (2019) FertiPROTEKT, oncofertility consortium and the Danish fertility preservation networks—what can we learn from their experiences? Clin Med Insights Reprod Health 2019(13):1179558119845865 von Wolff M, Nawroth F (Hrsg) (2020) FertiPROTEKT Netzwerk e. V. – Indikationen und Durchführung fertilitätsprotektiver Maßnahmen bei onkologischen und nicht-onkologischen Erkrankungen. Schmidt & Klaunig, Kiel Waks AG, Partridge AH (2016) Fertility preservation in patients with breast cancer: necessity, methods, and safety. J Natl Compr Canc Netw 14:355–363 Behringer K, Mueller H, Goergen H et al (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 trials. J Clin Oncol 31:231–239 Xu M, Pavone ME, Woodruff T (2011) Fruitful progress to fertility: preserving oocytes from chemodestruction. Nat Med 17:1562–1563 Lambertini M, Moore HCF, Leonard RCF et al (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 36:1981–1990 Regan MM, Walley BA, Francis PA et al (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225–2232 Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO), Kommission Mamma (2020) Diagnostik und Therapiefrüher und fortgeschrittener Mammakarzinome. https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2020/Alle_aktuellen_Empfehlungen_2020.pdf. Zugegriffen: 27. Juni 2020 Senra JC, Roque M, Talim MCT et al (2018) Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol 51:77–86 Chen H, Xiao L, Li J et al (2019) Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 3:CD8018 Lambertini M, Boni L, Michelotti A et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:2632–2640 Demeestere I, Brice P, Peccatori FA et al (2016) No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 34:2568–2574 von Wolff M, Bruckner T, Strowitzki T et al (2018) Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases—an analysis of 992 stimulations. J Assist Reprod Genet 35:1713–1739 Rienzi L, Romano S, Albricci L et al (2010) Embryo development of fresh ‘versus’ vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod 25:66–73 Lawrenz B, Jauckus J, Kupka M et al (2010) Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril 94:2871–2873 von Wolff M, Dittrich R, Liebenthron J et al (2015) Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5.000 women. Reprod Biomed Online 31:605–612 Doyle JO, Richter KS, Lim J et al (2016) Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril 105:459–466.e2 Cobo A, García-Velasco JA, Domingo J et al (2018) Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod 33:2222–2231 Diaz-Garcia C, Domingo J, Garcia-Velasco JA et al (2018) Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril 109:478–485.e2 Van der Ven H, Liebenthron J, Beckmann M et al (2016) Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod 31:2031–2041 Meirow D, Ra’anani H, Shapira M et al (2016) Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril 106:467–474 Jadoul P, Guilmain A, Squifflet J et al (2017) Efficacy of ovarian tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod 32:1046–1054 Gellert SE, Pors SE, Kristensen SG et al (2018) Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet 35:561–570 Fortin A, Azaïs H, Uzan C et al (2019) Laparoscopic ovarian tissue harvesting and orthotopic ovarian cortex grafting for fertility preservation: less is more. Fertil Steril 111:408–410 Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18:117–121 Mossa B, Schimberni M, Di Benedetto L et al (2015) Ovarian transposition in young women and fertility sparing. Eur Rev Med Pharmacol Sci 19:3418–3425